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PURPOSE: Endotoxins, also called 
lipopolysaccharides (LPS), are major contaminants 
found in commercially available proteins or 
biologically active substances, which often 
complicate study of the biological effects of the 
main ingredient. The presence of small amounts of 
endotoxin in recombinant protein preparations can 
cause side effects in host organism such as 
endotoxin shock, tissue injury, and even death. Due 
to these reactions, it is essential to remove 
endotoxins from drugs, injectables, and other 
biological and pharmaceutical products.  An 
overview of this subject is provided by this article. 
METHODS: An extensive review of literature with 
regard to methods for removal of endotoxin from 
biotechnological preparations was carried out. 
RESULTS: A short history of endotoxin is 
presented first. This is followed by a review of 
chemical and physical properties of endotoxin and 
its pathophysiological effects when the body is 
exposed to LPS excessively or systemically. The 
techniques of endotoxin determination and 
interaction of endotoxin with proteins is also 
presented, taking into consideration the established 
techniques as well as the state of the art technology 
in this field. A review of techniques of endotoxin 
removal from biotechnological preparations is 
described, emphasizing how endotoxin removal can 
be carried out in an economical way based on a 
number of processes discussed in the literature (e.g., 
adsorption, two-phase partitioning, ultrafiltration 
and chromatography). Different methods are 
mentioned with relatively high protein recoveries; 
however, special attention is given to two-phase 
aqueous micellar systems, which are valuable tools 
for endotoxin removal from pharmaceutical 
proteins on a small scale because they provide a 
mild environment for biological materials. 
CONCLUSIONS: Efficient and cost-effective 
removal of endotoxins from pharmaceutical and 
biotechnology preparations is challenging. Despite 
development of novel methods, such as the two-
phase aqueous micellar systems, in recent years, 




Endotoxins are lipopolysaccharides (LPS) derived 
from cell membrane of Gram-negative bacteria and 
are responsible for its organization and stability. In 
pharmaceutical industries it is possible to find 
endotoxins during production processes or in the 
final product. Although endotoxins are linked 
within the bacterial cell wall, they are continuously 
liberated into the environment. The release does not 
happen only with cell death but also during growth 
and division. Since bacteria can grow in nutrient 
poor media, such as water, saline, and buffers, 
endotoxins are found almost everywhere. A single 
Escherichia coli contains about 2 million LPS 
molecules per cell. Endotoxin elicits a wide variety 
of pathophysiological effects. In conditions where 
the body is exposed to LPS excessively or 
systemically (as when small concentrations of LPS 
enter the blood stream), a systemic inflammatory 
reaction can occur, leading to multiple 
pathophysiological effects, such as endotoxin 
shock, tissue injury, and death (1-3). However, 
endotoxin does not act directly against cell or 
organs but through activation of the immune 
system, especially through monocytes and 
macrophages, with the release of a range of pro-
inflammatory mediators, such as tumor necrosis 
factor (TNF), interleukin (IL)-6 and IL-1. Pyrogenic 
reactions and shock are induced in mammals upon 
intravenous injection of endotoxin at low 
concentrations (1 ng/mL) (4). 
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The maximum level of endotoxin for intravenous 
applications of pharmaceutical and biologic product 
is set to 5 endotoxin units (EU) per kg of body 
weight per hour by all pharmacopoeias (5). The 
term EU describes the biological activity of an 
endotoxin. For example, 100 pg of the standard 
endotoxin EC-5 and 120 pg of endotoxin from 
Escherichia coli O111:B4 have activity of 1 EU (6). 
Meeting this threshold level has always been a 
challenge in biological research and pharmaceutical 
industry (7, 8).  
 In the biotechnology industry, Gram-
negative bacteria are widely used to produce 
recombinant DNA products such as peptides and 
proteins. Many recombinant proteins are produced 
by the Gram-negative bacteria Escherichia coli. 
These products are always contaminated with 
endotoxins (6). For this reason, proteins prepared 
from Gram-negative bacteria must be as free as 
possible of endotoxin in order not to induce side 
effects when administered to animals or humans.  
However, endotoxins are very stable molecules, 
resisting to extreme temperatures and pH values in 
comparison to proteins (6, 8). Many different 
processes have been developed for the removal of 
LPS from proteins based on the unique molecular 
properties of the endotoxin molecules. These 
include LPS affinity resins, two-phase extractions, 
ultrafiltration, hydrophobic interaction 
chromatography, ion exchange chromatography, 
and membrane adsorbers. These procedures provide 
different degrees of success in the separation of 
LPS from proteins, which is highly dependent on 
the properties of the protein of interest (9). 
 The objective of this review is to discuss 
relevant aspects regarding endotoxin removal 
techniques from biotechnological preparations, 
considering its chemical and biological properties. 
Special attention will be given to removal by 
aqueous two-phase micellar systems using the 
surfactant Triton X-114. This review does not 
concentrate on the extracorporeal removal of 
endotoxin in vivo, which is the subject of other 
reviews (10-14). 
 
HISTORY OF ENDOTOXIN 
 
Studies about the occurrence of fever after 
intravenous administration of certain solutions are 
dated before the 19th Century. In 1894, Sanarelli 
showed that liquid cultures of Eberth bacillus, free 
from microorganisms, could produce an 
intoxication accompanied by fever when injected in 
animals, sometimes even lethal (15). By the end of 
the 19th Century, the designation “injection fever” 
was generally used to express the fever reactions 
observed after intravenous administration of several 
solutions. The administration of pharmaceuticals 
via intravenous route in the 20th Century increased 
the number of such accidents, leading several 
researchers to develop series of evaluating works 
about this subject. 
 In 1912, Hort and Penfold created the name 
“pyrogenic” to designate the “waters” which, when 
injected, cause “hyperthermia”. Such designation 
was retaken further, in 1923, by Florance Seibert, 
who called pyrogenic the “hyperthermizing” 
substances, which contained either dead bacteria – 
intact or disintegrated, pathogenic or not – or more 
often the bacterial metabolic products, such as the 
denaturized protein, endotoxins or exotoxins (16, 
17). 
 The term pyrogen became popular after 
frequent use by Seibert, and for that reason often its 
creation is attributed to him (17). Seibert and co-
workers continued the research started by Hort and 
Penfold, isolating a living Gram-negative 
microorganism from distillated water, which was 
able to produce pyrogens (15). The authors 
designated this microorganism as Pyrogenic 
bacterium, realizing that it was not a new bacterium 
since several varieties of microorganisms could 
produce pyrogens (16). 
 The major impulse given to increase the 
knowledge about pyrogens occurred between 1925 
and 1945. In particular, Co-Tui, helped by Schrift, 
deserves special credits for showing that Gram-
negative bacteria are the most dangerous producers 
of pyrogens. (18). It does not mean that Gram-
positive bacteria cannot generate such molecules; 
however, they do in a lower level. In fact, Gram-
positive bacteria, when destroyed by heat, produce 
almost no pyrogen, since in such bacteria exotoxins 
of proteic origin are generally formed, thus being 
easily denaturalized by heat. On the other hand, 
Gram-negative bacteria usually generate endotoxins 
composed mainly of lipopolysaccharides and, 
therefore, are more heat resistant than the first ones. 
According to Westphal (1945), the pyrogens, which 
shall really be feared in the pharmaceutical 
preparations, correspond to the endotoxins of 
Gram-negative bacteria, and such 
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lipopolysaccharide complexes are found in the outer 
layer of the bacterial cell wall (19). Essentially, 
pyrogens are originated in the microorganisms from 
the Enterobactereaceae family and are thought to 
be the main contaminant of an injectable solution 
prepared without the proper disinfecting and 
sterilizing processes. About two decades later, a 
collaborative study was developed by the US 
National Institutes of Health and 14 pharmaceutical 
industries to establish an animal system which 
would be adequate to evaluate the “pyrogenicity” of 
solutions. Such study culminated in the 
development of the first official pyrogen test in 
rabbits, which was incorporated in USP XII, in 
1942. In parallel, other efforts to purify and 
characterize the endotoxins have taken place, and 
isolated pyrogenics were obtained by several 
researchers (17, 19)  
 Shear and Turner (1943) were the first 
researchers to use the term lipopolysaccharide to 
name the endotoxin extract, a term that describes 
the nature of the endotoxin, and that has been 
adopted by the scientific community (20). In 1954, 
Westphal and collaborators detailed the use of 
water-phenol systems for the production of purified 
lipopolysaccharides (LPS), free of proteins, from 
several Enterobacteriaceae. (15, 21, 22). 
Consequently, in recent years great progress has 
been made in understanding the molecular 
organization and mechanisms underlying the 
detrimental and beneficial activities of endotoxins 
(8, 23). 
 
ENDOTOXIN: CHEMICAL AND PHYSICAL 
PROPERTIES 
 
Endotoxins, also called lipopolysaccharides (LPS), 
are a major component of the outer membrane of 
Gram-negative bacteria (Figure 1). They are 
composed of a hydrophilic polysaccharide moiety, 
which is covalently linked to a hydrophobic lipid 
moiety (Lipid A) (Figure 2) (3, 6, 24). LPS from 
most species is composed of three distinct regions: 
the O-antigen region, a core oligosaccharide and 
Lipid A (LipA) (Figure 2).  
Figure 1: Molecular model of the inner and outer membranes of E. coli K-12 according to Raetz et al., 1991 
(24). Geometric form: ovals and rectangles represent sugar residues, as indicated, whereas circles represent 
polar head groups of various lipids. Abbreviation: PPEtn (ethanolamine pyrophosphate); LPS 
(lipopolysaccharide); Kdo (2-keto-3-deoxyoctonic acid).  

























Figure 2: Chemical structure of endotoxin from E. coli O111:B4 according to Ohno and Morrison 1989 (25). 
(Hep) L-glycerol-D-manno-heptose; (Gal) galactose; (Glc) glucose; (KDO) 2-keto-3-deoxyoctonic acid; (NGa) 
N-acetyl-galactosamine; (NGc) N-acetyl-glucosamine. 
 
The lipid A is the most conserved part of 
endotoxin (8, 26) and is responsible for most of the 
biological activities of endotoxin, i.e. its toxicity. 
Endotoxin is composed of β-1,6-linked D-
glucosamine residues, covalently linked to 3-
hidroxy-acyl substituents with 12-16 carbon atoms 
via amide and ester bonds. These can be further 
esterified with saturated fatty acids. This 
hydrophobic part of endotoxin adopts an ordered 
hexagonal arrangement, resulting in a more rigid 
structure compared to the rest of the molecule (8, 
9). Strains lacking lipid A or endotoxin are not 
known.  The core oligosaccharide has a conserved 
structure with an inner 3-deoxy-D-manno-2-
octulosonic acid (KDO) - heptose region and an 
outer hexose region. In E. coli species, five 
different core types are known, and Salmonella 
species share only one core structure. The core 
region close to lipid A and lipid A itself are 
partially phosphorylated (pK1=1.3, pK2 = 8.2 of 
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phosphate groups at lipid A), thus endotoxin 
molecules exhibit a net negative charge in common 
protein solutions (8, 27). The O-antigen is generally 
composed of a sequence of identical 
oligosaccharides (with three to eight 
monosaccharides each), which are strain specific 
and determinative for the serological identity of the 
respective bacterium (8).  
The molar mass of an endotoxin monomer 
varies from 10 to 20 kDa, owing to the variability 
of the oligosaccharide chain; even extreme masses 
of 2.5 (O-antigen-deficient) and 70 (very long O-
antigen) kDa can be found. It is well known that 
endotoxins form various supra-molecular 
aggregates in aqueous solutions because of their 
amphipathic structures. These aggregates result 
from non-polar interactions between lipid chains as 
well as of bridges generated among phosphate 
groups by divalent cations (1). The aggregate 
structures have been studied by numerous 
techniques such as electron microscopy, X-ray 
diffraction, FT-IR spectroscopy, and NMR. Results 
from these studies have shown that, in aqueous 
solutions, endotoxins can self assemble in a variety 
of shapes, such as lamella, cubic, and hexagonal 
inverted arrangements, with diameters up to 0.1 μm 
and 1000 kDa, and high stability depending on the 
solution characteristics (pH, ions, surfactants, etc) 
(28, 29). It is proposed that proteins may also shift 
equilibrium by releasing endotoxin monomers from 
aggregates (6, 8). According to molecular 
dynamics, the three-dimensional structure of 
endotoxin, especially the long surface antigen, is 
much more flexible than the globular structure of 
proteins (8).  
 Endotoxins are shed in large amount upon 
cell death as well as during growth and division. 
They are highly heat-stable and are not destroyed 
under regular sterilizing conditions. Endotoxin can 
be inactivated when exposed at temperature of 250º 
C for more than 30 minutes or 180º C for more than 
3 hours (28, 30). Acids or alkalis of at least 0.1 M 
strength can also be used to destroy endotoxin in 
laboratory scale (17). 
 
MECHANISM OF ENDOTOXIN ACTION 
 
Endotoxin elicits a wide variety of 
pathophysiological effects, such as endotoxin 
shock, tissue injury, and death (3). Endotoxins do 
not act directly against cells or organs but through 
activation of immune system, especially the 
monocytes and macrophages, thereby enhancing 
immune responses. These cells release mediators, 
such as tumour necrosis factor, several interleukins, 
prostaglandins, colony stimulating factor, platelet 
activating factor and free radicals (31, 32). The 
mediators have potent biological activity and are 
responsible for the side effects upon endotoxin 
exposure. These include alterations in the structure 
and function of organs and cells, changes in 
metabolic functions, increased body temperature, 
activation of the coagulation cascade, modification 
of hemodynamics and induction of shock. Many 
attempts have been made to prevent or treat the 
deleterious effects of endotoxins on immune cells, 
such as the use of anti-endotoxin antibodies, and 
endotoxin partial structures for blocking endotoxin 
receptor antagonists. Nevertheless, the interaction 
of endotoxins with immune cells is not only 
mediated by specific receptors. Cell priming may 
also occur by non-specific intercalation of 
endotoxin molecules into the membranes of the 
target cells (33). 
 Finally, it should be mentioned that 
endotoxins may also have beneficial effects. They 
have been used in artificial fever therapy, to destroy 
tumors and to improve, non-specifically, the 
immune defense. The uncertainty about its role for 
the human health was once described by Bennett 
(34). On the other hand, any superfluous endotoxin 
exposure must be strictly avoided to prevent 
complications. This is especially true for 
intravenously-administered medicines.  
 
 
TECHINIQUES OF ENDOTOXIN DETERMIN 
-ATION 
 
The commonly used FDA-approved 
techniques for endotoxin detection are the rabbit 
pyrogen test and Limulus Amoebocyte Lysate 
(LAL) assay (35, 36). The rabbit pyrogen test, 
developed in the 1920s, involves measuring the rise 
in temperature of rabbits after intravenous injection 
of a test solution. Due to its high cost and long 
turnaround time, the use of the rabbit pyrogen test 
has diminished, and is now only applied in 
combination with the LAL test to analyze biological 
compounds in the earlier development phase of 
parenteral devices. Today the most popular 
endotoxin detection systems are based on LAL, 
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which is derived from the blood of horseshoe crab, 
Limulus polyphemus, and clots upon exposure to 
endotoxin. The simplest form of LAL assay is the 
LAL gel-clot assay. When LAL assay is combined 
with a dilution of the sample containing endotoxin, 
a gel will be formed proportionally to the endotoxin 
sensitivity of the given assay. The endotoxin 
concentration is approximated by continuing to use 
an assay of less sensitivity until a negative reaction 
(no observable clot) is obtained. This procedure can 
require several hours (5, 36). The concentration of 
0.5 EU/mL was defined as the threshold between 
pyrogenic and non-pyrogenic samples (17, 36).  
In addition to the gel-clot technique, 
manufacturers have also developed two other 
techniques: turbidimetric LAL technique and the 
chromogenic LAL technique. These newer 
techniques are kinetic based, which means they can 
provide the concentration of endotoxin by 
extracting the real-time responses of the LAL assay. 
Turbidimetric LAL assay contains enough 
coagulogen to form turbidity when cleaved by the 
clotting enzyme, but not enough to form a clot (37). 
The LAL turbidimetric assay, when compared to 
the LAL gel-clot assay, gives a more quantitative 
measurement of endotoxin over a range of 
concentrations (0.01 EU/mL to 100.0 EU/mL.). 
This assay is based on the turbidity increase due to 
protein coagulation related to endotoxin 
concentration in the sample. The optical densities of 
various test-sample dilutions are measured and 
correlated to endotoxin concentration helped by a 
standard curve obtained from samples with known 
amounts of endotoxin (38). A kinetic chromogenic 
substrate assay differs from gel-clot and 
turbidimetric reactions because the coagulogen is 
partially or completely replaced by a chromogenic 
substrate (39). When hydrolyzed by the pre-clotting 
enzyme, the chromogenic substrate releases a 
yellow-colored substance known as p-nitroaniline. 
The time required to attain the yellow substance is 
related to the endotoxin concentration (40). 
However, kinetic turbidimetric and chromogenic 
tests, although more accurate and faster than the 
gel-clot, can not be used for fluids with inherent 
turbidity such as blood and yellow-tinted liquids, 
e.g. urine, and their performance may be 
compromised by any precipitation from solution 
(37). Therefore, different methods for detection of 
endotoxin in different samples have been studied 
(37, 41). 
INTRACTIONS OF ENDOTOXINS WITH 
PROTEINS  
 
A number of biomolecules show 
interactions with endotoxins, such as 
lipopolysaccharide-binding protein (LBP), 
bactericidal/permeability-increasing protein (BPI), 
amyloid P component, cationic protein (42, 43), or 
the enzyme employed in the biological endotoxin 
assay (anti-LPS) factor from Limulus amebocyte 
lysate (LAL) (44). These proteins are directly 
involved in the reaction of many different species 
upon administration of endotoxin (45, 46). 
Molecular recognition can be assumed as 
interactions with anti-endotoxin antibodies and 
proteineous endotoxin receptors (e.g. CD14, CD16, 
CD18) (47). Other proteins interact with endotoxins 
even having no strong links to a biological 
mechanism, such as lysozyme (25) and lactoferrin 
(48), which are basic proteins (pI>7), electrostatic 
interactions can be assumed as the main driving 
force. Regardless of the mechanism that proves to 
be most significant, these interactions result in 
hiding endotoxin molecules, and consequently these 
molecules are not removed in the removal 
procedures. A typical example is described by 
Karplus et al.  (49).  
However, other mechanisms must exist as 
interactions with neutral hemoglobin (50) and even 
acidic proteins (pI<7) are known, taking place also 
at low ionic strength. It is still controversially 
discussed how these interactions occur. Generally, 
hydrophobic interactions with proteins are 
conceivable. However, there is no strong evidence 
that it drives the interaction mechanism. It is more 
probable that competition of protein-bound 
carboxylic groups and endotoxin-bound phosphoric 
acid groups for Ca2+ may result in dynamically 
stable calcium bridges between proteins and 
endotoxins (8). 
The fact that LPS forms micellar aggregates 
that are considered the biologically active forms of 
LPS (51) could indicate that multiple proteins 
interact with LPS molecules. Ma et al. (2006) (52) 
suggested an alternative aggregation form, where 
the self-assembly of lipophorin particles, a protein 
that serves as pro-coagulant (53-55), into globular 
structures are the result of oligomeric interactions. 
This may provide cage-like coagulation products, 
where the lipid moiety forms a protective layer that 
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separates the toxin from interaction with the 
surrounding environment. 
Due to protein–endotoxin interactions, 
endotoxin removal from protein solutions requires 
techniques that are able to generate strong 
interactions with endotoxins, such as affinity 
chromatography. Alternatively, a specific 
dissociation of protein–endotoxin complexes may 
improve the availability of endotoxin molecules for 
removal. In view of the large variety of products, it 
is not possible to develop one general method for 
endotoxins removal from all products. 
 
TECHNIQUES OF ENDOTOXIN REMOVAL  
 
The question about how endotoxin removal 
can be carried out in an economical way has 
attracted the attention of many investigators and has 
been – although not published – the reason for 
process rearrangements in many cases. However, 
this issue has not yet been resolved satisfactorily. 
The discussion of relevant aspects of endotoxin 
removal from biological preparations and a critical 
review of the existing approaches are mandatory in 
order to develop more refined methods in the 
future.  
In the pharmaceutical industry several 
alternative routes are known to generate products 
with low-endotoxin levels. However, their diversity 
indicates a dilemma in endotoxin removal. Several 
procedures were developed for pharmacoproteins, 
taking advantage of the characteristics of the 
production process, tailored to suit specific product 
requirements. Therefore, each procedure addresses 
the problem in a completely different way; none of 
them turns out to be broadly applicable. Anionic-
exchange chromatography, for example, is 
potentially useful for the decontamination of 
positively-charged proteins, such as urokinase (56). 
However, decontamination of negatively-charged 
proteins would be accompanied by a substantial 
loss of the product due to adsorption (27, 57). For 
small proteins, such as myoglobin (Mr ~ 18000 Da), 
ultrafiltration can be useful to remove large 
endotoxin aggregates. With large proteins, such as 
immunoglobulins (Mr ~ 150000 Da) ultrafiltration 
would not be effective. In addition, ultrafiltration 
would fail if interactions between endotoxins and 
proteins cause endotoxin monomers to permeate 
with proteins pick-a-pick through the membrane. 
Endotoxins can be considered to be 
temperature and pH stable, rendering their removal 
as one of the most difficult tasks in downstream 
processes during protein purification (58, 59). The 
removal of endotoxins becomes more challenging 
when associated with labile biomolecules, such as 
proteins (60). A number of approaches are typically 
utilized to reduce endotoxin contamination of 
protein preparations, including ion-exchange 
chromatography (61, 62), affinity adsorbents, such 
as immobilized L-histidine, poly-L-lysine, poly(γ-
methyl L-glutamate), and polymyxin B (57, 63, 64), 
gel filtration chromatography, ultrafiltration, 
sucrose gradient centrifugation (65), and Triton X-
114 phase separation (66, 67). The success of these 
techniques in separating LPS from proteins is 
strongly dependent on the properties of the target 
protein (9). 
Two important factors influencing the success 
of any approach are the affinity of the endotoxin 
and protein antigen for the chromatography support 
or media used and the affinity of the endotoxin for 
the protein antigen. A third factor is how the 
affinity of the endotoxin for the protein can be 
modified by factors such as temperature, pH, 
detergents (surfactants), solvents and denaturants 
(4). 
Usually, the procedures employed for 
endotoxin removal are unsatisfactory regarding 
selectivity, adsorption capacity and recovery of the 
protein. In the selective removal of endotoxin from 
protein-free solutions, it is easy to remove 
endotoxins by ultrafiltration taking advantage of the 
different sizes of the endotoxin and water, or by 
non-selective adsorption with hydrophobic 
adsorbent (68) or an anion-exchanger (69). For 
selective removal of endotoxin from protein 
solutions, it is necessary to know what is the form 
of the endotoxins in protein solutions. 
Hirayama and Sakata (2002) (6) assumed that 
endotoxin aggregates form supermolecular 
assemblies with phosphate groups as the head group 
and exhibits a negative net charge because of its 
phosphate groups that originate from lipid A (6). 
These characteristics suggest that ionic interaction 
plays an important role in the binding between the 
cationic adsorbent and phosphate groups of the 
endotoxins. When hydrophobic adsorbents are used 
in protein solutions, it is suggested that there is also 
hydrophobic binding between the adsorbent and the 
lipophilic groups of endotoxins. These binding 
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processes depend on the properties of proteins (net 
charge, hydrophobicity) and the solution conditions 
(pH, ionic strength). 
Some commonly used techniques for removing 
endotoxin contaminants are ultrafiltration (70) and 
ion exchange chromatography (71). Ultrafiltration, 
although effective in removing endotoxins from 
water, is an inefficient method in the presence of 
proteins, which can be damaged by physical forces 
(72). Anion exchangers, which take advantage of 
the negative net charge of endotoxins, have been 
extensively used for endotoxin adsorption. 
However, when negatively charged proteins need to 
be decontaminated, they may co-adsorb onto the 
matrix and cause a significant loss of biological 
material. Also, net-positively charged proteins form 
complexes with endotoxins, causing the proteins to 
drag endotoxin along the column and consequently 
minimizing the endotoxin removal efficiency (57). 
Alkanediols were shown to be effective 
agents for the separation of LPS from LPS-protein 
complexes during chromatography with ionic 
supports. Their effectiveness in reducing the protein 
complexation with LPS is dependent on (I) the size 
of the alkanediol, (II) the isomeric form of the 
alkanediol, (III) the length of the alkanediol wash, 
(IV) the concentration of alkanediol, and (V) the 
type of ionic support used, cationic or anionic. 
Alkanediol are non-flammable and as such are safer 
alternatives when compared to alcohols (ethanol or 
isopropanol) which have also been used to remove 
LPS from protein-LPS complexes (9). LPS removal 
is more efficient on cationic exchangers than on 
anionic exchangers.  
In order to remove endotoxin from 
recombinant protein preparations, the protein 
solution may be passed through a column that 
contains polymyxin B immobilized on Sepharose 
4B, in the hope that contaminating endotoxin binds 
to the gel. Similarly, histidine immobilized on 
Sepharose 4B also has the capability to capture 
endotoxin from protein solutions (63). Polymyxin B 
affinity chromatography is effective in reducing 
endotoxin in solutions (73). Polymyxin B, a peptide 
antibiotic, has a very high binding affinity for the 
lipid A moiety of most endotoxins (74). Karplus et 
al. (1987) (49) reported an improved method of 
polymyxin B affinity chromatography in which 
endotoxin could be absorbed effectively after 
dissociation of the endotoxin from the proteins by a 
nonionic detergent, octyl-β-D-glucopyranoside.  
The methods mentioned above are 
reasonably effective for removal of endotoxins from 
protein solutions with relatively high protein 
recoveries. However, these affinity phases cannot 
be cleaned with standard depyrogenation conditions 
of strong sodium hydroxide in ethanol (75). 
Anspach and Hillbeck (1995) (57) revealed that 
these supports suffer from considerable efficiency 
decrease in the presence of proteins. Hence, they 
are not in general applicable for the above 
mentioned problem (57).  
 Membrane-based chromatography has been 
successfully employed for preparative separations 
predominantly for protein separations (76-83). 
Nevertheless, universal adoption of this technology 
has not taken place because membrane 
chromatography is limited by the binding capacity, 
which is small when compared to that of bead-
based columns, even though the high flux 
advantages provided by membrane adsorbers would 
lead to higher productivity (78). Although bead-
based chromatography is still predominant and 
affective for product elution operations, it has 
several inherent disadvantages for trace-impurity 
removal or polishing applications. Furthermore, the 
adsorptive binding capacity of bead-based columns 
used in this application is typically 3-4 orders of 
magnitude larger than required because columns are 
normally sized to achieve a desired flow rate rather 
than capacity. Since membrane-based systems have 
a distinct flow rate advantage and sufficient 
capacity for binding trace levels of impurities and 
contaminants, membrane adsorbers are ideally 
suited for this application. Work has been done 
recently using membrane chromatography to 
remove DNA, host cell protein (HCP) and 
endotoxin with reasonable success (8, 84-86). 
 Jann et al., (1975) (87) reported that slab-
polyacrylamide gel electrophoresis in the presence 
of sodium dodecyl sulfate (SDS-PAGE) can be 
used for the separation of bacterial LPS. The 
authors showed that LPS molecular structures could 
be assigned to the separated LPS bands by 
correlating the electrophoretic banding pattern, as 
detected with periodic acid-Schiff stain, with the 
chromatography profile generated by gel 
permeation of chemically characterized 
carbohydrate moieties released from the LPS. 
While LPS obtained from rough (R) mutant 
bacteria, which contained a short oligosaccharides 
chain, exhibited only a fast-moving band, the LPS 
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from wild-type smooth (S) strains, which had a core 
oligosaccharide substituted with various sizes of the 
O-specific polysaccharide chain, showed both fast 
and slow-migrating bands. On the other hand, LPS 
from the semirough (SR)-type bacteria containing a 
core oligosaccharide and truncated O-chain were 
detected as a fast-moving band migrating somewhat 
slower than R-type LPS bands. In spite of this great 
advance in the separation and analysis of intact 
LPS, the limited sensitivity of detection that 
resulted in the visualization of few broad and 
diffused LPS bands hindered the uncovering of 
further molecular intricacies of LPS (88). LPS from 
smooth and rough strains may be dispersed by 
surfactants such as sodium dodecyl sulfate (89, 90), 
Triton X-100 (91), and sodium deoxycholate (92-
94). Upon removal of excess surfactant by dialysis, 
a more homogeneous population of particles with 
average molecular weight of about 5x105 to 
1x106 Da is formed. Such observations suggest that 
hydrophobic interactions between subunits of LPS 
are important determinants of particle size (92). 
 Several methods have been used to separate 
the different subclasses of LPS from individual 
strains, with sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) 
(87-95) and gel filtration (96) being perhaps the 
most successful. These methods are, however, 
hampered by the tendency of LPS to aggregate and 
by the difficulty in detecting and identifying each 
distinct subclass (97). Agarose-gel electrophoresis 
has been used for various purposes, such as to 
separate polysaccharides extracted from tissues, 
organs, and biological fluids of invertebrates and 
vertebrates (97-100). Furthermore, densiometric 
band analysis enables one to obtain quantitative 
evaluation of single polysaccharide species in 
mixtures (97).  
Although common purification protocols may 
reduce the endotoxin content below the threshold 
level, an absolute guarantee cannot be given. It may 
happen that a batch of the final products is 
accidentally contaminated and fails the quality 
control. This product has to be discarded; 





TWO-PHASE MICELLAR SYSTEM 
 
 In recent years, the interest in the use of 
two-phase aqueous micellar systems for the 
purification or concentration of biological 
molecules, such as proteins and viruses has been 
growing (101-103). In these systems an aqueous 
surfactant solution, under the appropriate solution 
conditions, spontaneously separates into two 
predominantly aqueous, yet immiscible, liquid 
phases, one of which has a greater concentration of 
micelles than the other (101). The difference 
between the physicochemical environments in the 
micelle-rich phase and in the micelle-poor phase 
forms the basis of an effective separation and makes 
two-phase aqueous micellar systems a convenient 
and potentially useful method for the separation, 
purification, and concentration of biomaterials 
(101).  
 In their simplest realization, these systems 
exploit excluded-volume interactions between 
nonionic surfactant micelles and biomolecules. 
Specifically, in the phase-separated system one of 
the coexisting phases is rich in micelles while the 
order is poor in micelles (Figure 3) (104, 105). As a 
result, the stronger excluded-volume interactions 
between the nonionic surfactant micelles and the 
biomolecules in the micelle-rich phase drive the 
biomolecules preferentially into the micelle-poor 
phase based on their sizes (106).  
Particularly for endotoxin removal, above 
the critical micelle concentration (CMC) of 
surfactants, endotoxins are accommodated in the 
micellar structure by non-polar interactions of alkyl 
chains of lipid A and the surfactant tail groups and 
are consequently separated from the water phase 
(micelle-poor phase). Surfactants of the Triton 
series show a miscibility gap in aqueous solutions. 
Above a critical temperature, the so-called cloud 
point, micelles aggregate to droplets with very low 
water content, by that forming a new phase. 
Endotoxins remain in the surfactant-rich phase. 
Through centrifugation or further increase in 
temperature the two-phases separate with the 
surfactant-rich phase being the bottom phase (66, 
105, 107). If necessary, this process is repeated 
until the remaining endotoxin concentration is 
below the threshold limit. The cloud point of Triton 
X-114 is at 22°C, which is advantageous when 
purifying proteins. 
 

















Figure 3: Schematic illustration of a Triton X-114 micellar solution phase separation, upon temperature 
increase. Each of the resulting coexisting phases contains cylindrical micelles but at different micellar 
concentrations. Note also that, on average, the cylindrical micelles in the micelle-rich (bottom) phase are larger 
than those in the micelle-poor (top) phase. 
 
Using Triton X-114, Adam et al. (1995) 
(108) showed a 100-fold endotoxin reduction in two 
steps with a final endotoxin content of 30 EU mg-1 
and 50% loss in bioactivity of the 
exopolysaccharide. In addition, about 100-fold 
endotoxin reduction was shown by Cotten et al. 
(1994) (109), from plasmid DNA preparation with a 
final endotoxin content of 0.1 EU in 6 μg DNA.  
A comparison of affinity adsorption and 
Triton X-114 two-phase extraction for the 
decontamination of the recombinant proteins 
cardiac troponin I, myoglobin and creatine kinase 
isoenzymes is described by Liu et al. (1997) (67). 
They concluded that phase separation was the most 
effective method, reducing the endotoxin content by 
98-99% with remaining amounts of 2.5-25 EU mg-1, 
depending on the protein. However, Cotton et al. 
(1994) (109) observed slightly better removal 
efficiency with a polymyxin B sorbent.  
 Aida and Pabst (1990) (66) reported a 
method to reduce endotoxin in protein solutions 
using Triton X-114, in which the surfactant aids in 
dissociation of endotoxin from the protein, while 
also providing a convenient phase separation 
capability for removing the dissociated endotoxin. 
According to these same authors, phase separation 
using Triton X-114 was effective in reducing 
endotoxin from solutions of three different proteins 
(cytochrome c, albumin and catalase). The first 
cycle of phase separation reduced endotoxin 
contamination by 1000-fold. Further cycles of 
phase separation resulted in complete removal of 
endotoxin. The endotoxin was found in the 
detergent phase, and the upper aqueous phase 
contained the desired biomolecule. In addition to 
decontamination of endotoxin from protein 
preparation like recombinant products or 
monoclonal antibodies, phase separating using 
Triton X-114 should be useful for the removal of 
lipids from albumin or lipoproteins. Considering 
that a certain amount of surfactant always remains 
in the protein solution, which needs to be removed 
by additional adsorptions or gel filtration processes, 
this process leads to 10-20% product loss (66). It 
has been proposed that the detergent dissociates the 
endotoxin molecule from the protein and separates 
the dissociated molecule by phase separation using 
the physical characteristics of Triton X-114 (66). 
Liu et al. (1997) (67) demonstrated that the Triton 
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other recombinant protein preparations. By 
performing three cycles of Triton X-114 phase 
separation, endotoxin levels in all recombinant 
proteins derived from E. coli were reduced by as 
much as 99% of the original amount. Furthermore, 
the immunoactivity, physical integrity, and the 
biological activity of the protein remained 
unchanged after the phase separation process. The 
phase separation can be repeated multiple times 
until endotoxin in the aqueous phase reaches a 
satisfactory level. In addition to its simplicity, this 
procedure is cost effective, especially in large scale. 
 Fiske et al. (2001) (4) examined a number 
of approaches to reduce the level of endotoxin, such 
as the use of the zwitterionic surfactants 
Zwittergent 3-12 (Z3-12) and Zwittergent 3-14 
(Z3-14) for the dissociation of endotoxin from the 
purified UspA2 protein and the subsequent 
separation of endotoxin from UspA2 using either 
ion-exchange or gel filtration chromatography. 
UspA2 protein is a potential vaccine candidate for 
preventing otitis media and other diseases caused 
by Moraxella catarrhalis (110). The approach that 
was proved successful for the dissociation of 
endotoxin from UspA2 was the replacement of the 
Triton X-100 by a zwitterionic surfactant. The 
inability of Triton X-100 to dissociate the 
endotoxin-UspA2 complex, despite success of both 
Z3-12 and Z3-14 may reside in the charge 
characteristics of the surfactants. Triton X-100 is a 
non-ionic surfactant containing no charged moieties 
while the Zwittergents contain zwitterionic head 
groups with both negatively and positively charged 
moieties. Most zwitterionic surfactants are 
effectively neutral; however, in some cases strong 
polarization exists (111). The charge characteristics 
of Z3-12 and Z3-14 and the interaction of the 
surfactant with either the endotoxin and/or the 
protein may aid in the dissociation of the endotoxin 
from protein (in this case UspA2). Structural 
differences between the surfactants may also play a 
role in effective dissociation of endotoxin and 
protein. Whatever the mechanism, the use of the 
Zwittergent surfactant was proved to be quite 
suitable for the removal of LPS from UspA2 
without disrupting the immunogenic properties of 
the protein. Prior to endotoxin reduction, the UspA2 
preparations contained as much as 158 EU/Kg. 
However, following chromatography in the 
presence of Z3-12 Fiske et al. (2001) (4) achieved 
levels of approximately 0.0072 EU/Kg. The 
endotoxin removal process has been successfully 
implemented following GMP, to produce UspA2 
subunit vaccine for clinical trials. 
The levels of endotoxin appear to be much 
higher in recombinant proteins derived from soluble 
or cytoplasmatic fractions than in proteins derived 
from insoluble or inclusion bodies. This is 
consistent with the belief that lipopolysaccharides 
present in the cell wall are solubilized during the 
cell lysis procedure. Schnaitman (112) 
demonstrated that treatment of E. coli with the 
combination of Triton X-114, EDTA, and lysozyme 
resulted in solubilization of all lipopolysaccharide 
from the cell wall. 
Reichelt et al. (2006) (59) tested whether 
the removal of endotoxin could be achieved during 
chromatography purification with the use of Triton 
X-114 in the washing steps. The application of 
0.1% Triton X-114 in the washing steps was 
successful at reducing endotoxins during histidine 
and GST (resin GST sepharose) fusion protein 
purification, whereas washing steps lacking 
surfactant were ineffective in eliminating 
endotoxins. In contrast to purified materials 
employing the standard protocol which contained 
from 2500 to 34000 EU mg-1, purified recombinant 
proteins treated with Triton X-114 contained 
concentrations as low as 0.2 to 4 EU mg-1 (less than 
1% of initial endotoxin content). Residual 
endotoxins in solubilized inclusion bodies can reach 
levels of 8 x 106 EU mL-1 despite the fact that 
endotoxin levels were found to be higher in 
recombinant proteins which are isolated from 
soluble fractions (113). 
Endotoxins have been shown to form 
complexes with proteins of different isoelectric 
points (8) where electrostatic interactions are 
thought to be the main driving forces. As a result, 
the removal of endotoxins from basic proteins 
should prove to be more difficult than from acidic 
proteins (114). Reichelt et al. (2006) (59) studied 
whether the use of Triton X-114 in washing steps 
could eliminate endotoxins from proteins with a pI 
above 8.5. They found that washing with Triton X-
114 coupled with affinity chromatography 
effectively removed endotoxins from negatively-
charged proteins (SyCRP and NdhR). The minimal 
endotoxin concentration achieved was lower than 
0.2 EU mg-1; protein recovery and yield were close 
to 100% (59). 
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Temperature-induced phase separation with 
Triton X-114 is a recent and powerful technique 
which efficiently separates hydrophobic and 
hydrophilic membrane proteins at room 
temperature, without denaturation (107, 115). This 
method was also successfully applied to the 
removal of endotoxin from proteins and enzymes, 
while retaining their normal functions (66). Because 
of an amphipathic character, LPS was also 
significantly removed from Klebsiella sp I-714 EPS 
(extracellular polysaccharides termed 
exopolysaccharides) after two extractions steps in 
2% Triton X-114, with only a twofold decrease in 
bioactivity (108). According to the same authors, 
the Triton X-114 partitioning technique is fast, 
efficient, nondegradative, and allows a high level of 
detoxification of the Klebsiella sp. I-714 EPS. The 
separation of endotoxin and exopolysaccharides 
from Klebsiella sp. I-714 is difficult to achieve with 
techniques other than two-phase extraction. In 
addition, this method has also been successfully 
employed for the purification of an endotoxin-
contaminated negatively-charged EPS from 
Pseudomonas solanacearum (108).  
The detergents, even though they were also 
very effective at reducing the LPS levels, are 
relatively expensive, would add significant cost to a 
manufacturing process, and may affect the 
bioactivity of the protein of interest. Alternative 
chemicals are desired that could safely and cost 
effectively be used in place of the alcohols or 
detergents as washing agents for the separation of 
LPS from proteins during chromatographic unit 
operations. Ideally, these chemicals would be 
relatively inexpensive, chemically well defined, 
present minimal safety issues, and have minimal 
impact on the bioactivity of the protein in question 




Taking into consideration the properties of 
two-phase aqueous micellar systems to remove 
biomolecules, this research group had some 
promising results, using Triton X-114 to remove 
endotoxins present in fermented culture of E. coli 
cells during the production of protein.  According to 
the literature ([7], [58], [65], [107]), phase 
separation using Triton X-114 was effective in 
reducing endotoxin from solutions containing 
biomolecules, however the optimized conditions are 
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